What to expect from HER-2 directed therapies in advanced gastric cancer?

被引：1
|
作者：
Dane, Faysal [1 ]
机构：
[1] Marmara Univ, Sch Med, Dept Internal Med, Div Med Oncol, Mimar Sinan Caddesi 41 Ust Kaynarca Fevzicakmak M, Istanbul, Turkey
来源：
MARMARA MEDICAL JOURNAL | 2015年 / 28卷 / 04期
关键词：
Gastric cancer; HER-2/neu; Targeted therapy;
D O I：
10.5472/mmj.87204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma.
引用
收藏
页码：11 / 15
页数：5
相关论文
共 50 条
  • [31] Targeted Therapies in Advanced Gastric Cancer
    Patel, Timil H.
    Cecchini, Michael
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (09)
  • [32] Targeted HER2 Treatment in Advanced Gastric Cancer
    Jorgensen, Jan Trost
    ONCOLOGY, 2010, 78 (01) : 26 - 33
  • [33] HER-2/neu Assessment for Gastric Carcinoma: Validation of Scoring System
    Mrklic, Ivana
    Bendic, Antonia
    Kunac, Nenad
    Bezic, Josko
    Forempoher, Gea
    Durdov, Merica Glavina
    Karaman, Ivana
    Prusac, Ivana Kuzmic
    Pisac, Valdi Pesutic
    Vilovic, Katarina
    Tomic, Snjezana
    HEPATO-GASTROENTEROLOGY, 2012, 59 (113) : 300 - 303
  • [34] Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients
    Sasaki, Takahide
    Fuse, Nozomu
    Kuwata, Takeshi
    Nomura, Shogo
    Kaneko, Kazuhiro
    Doi, Toshihiko
    Yoshino, Takayuki
    Asano, Hiromichi
    Ochiai, Atsushi
    Komatsu, Yoshito
    Sakamoto, Naoya
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 43 - 48
  • [35] Her-2/neu and breast cancer
    Kaptain, S
    Tan, LK
    Chen, BY
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2001, 10 (03) : 139 - 152
  • [36] HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles
    Brian C. Grieb
    Rajiv Agarwal
    Current Treatment Options in Oncology, 2021, 22
  • [37] HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles
    Grieb, Brian C.
    Agarwal, Rajiv
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (10)
  • [38] Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tissues of Patients with Gastric Cancer and Expression Correlation Between HER-2 and LRP
    Zhou, Pengzhe
    Yu, Honghai
    Zhang, Gang
    Zhang, Jinzhuo
    Hao, Yingxia
    ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY, 2019, 41 (01): : 9 - 15
  • [39] Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways
    Haiyong Wang
    Jun Lu
    Jian Tang
    Shitu Chen
    Kuifeng He
    Xiaoxia Jiang
    Weiqin Jiang
    Lisong Teng
    BMC Cancer, 17
  • [40] Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients
    He, Lijuan
    Liu, Ben
    Wang, Zhuanfang
    Han, Qinying
    Chen, Hao
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2025, : 260 - 277
12345